October 23, 2014 | Beta-O2 Technologies announced that the company’s first broad study of the ßAir Bio-Artificial Pancreas has been successfully implanted. ßAir is a treatment still under development for Type I diabetes, with hope that it may even be a cure. The eight participants in the study will be treated and observed at Uppsala University Hospital in Sweden. According to Beta-O2 chairman, if the eight-person trial is successful, it will be necessary to carry out an efficacy trial on an addition 50 patients, after which it will be possible to market the product. Beta-O2 was founded in 2004 and is headquartered in Rosh HaAyin, Israel.